These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27106693)

  • 1. Longitudinal Assessment Design and Statistical Power for Detecting an Intervention Impact.
    Petras H
    Prev Sci; 2016 Oct; 17(7):819-29. PubMed ID: 27106693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes.
    Austin PC
    Stat Med; 2007 Aug; 26(19):3550-65. PubMed ID: 17238238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An investigation of the statistical power of the effect size in randomized controlled trials for the treatment of patients with type 2 diabetes mellitus using Chinese medicine].
    Ma LX; Liu JP
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jan; 32(1):119-23. PubMed ID: 22500409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A priori power analysis in longitudinal three-level multilevel models: an example with therapist effects.
    de Jong K; Moerbeek M; van der Leeden R
    Psychother Res; 2010 May; 20(3):273-84. PubMed ID: 19946814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
    Nie L; Chu H; Cole SR
    Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size and power calculations for medical studies by simulation when closed form expressions are not available.
    Landau S; Stahl D
    Stat Methods Med Res; 2013 Jun; 22(3):324-45. PubMed ID: 22491174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness.
    Gould AL; Koglin J; Bain RP; Pinto CA; Mitchel YB; Pasternak RC; Sapre A
    Clin Trials; 2009 Aug; 6(4):305-19. PubMed ID: 19667027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Power analysis for idiographic (within-subject) clinical trials: Implications for treatments of rare conditions and precision medicine.
    Tueller S; Ramirez D; Cance JD; Ye A; Wheeler AC; Fan Z; Hornik C; Ridenour TA
    Behav Res Methods; 2023 Dec; 55(8):4175-4199. PubMed ID: 36526885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapists as fixed versus random effects-some statistical and conceptual issues: a comment on Siemer and Joormann (2003).
    Crits-Christoph P; Tu X; Gallop R
    Psychol Methods; 2003 Dec; 8(4):518-23. PubMed ID: 14664686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: efficient rehabilitation trial designs using disease progress modeling: a pediatric traumatic brain injury example.
    Forsyth R; Thuy Vu ; Salorio C; Christensen J; Holford N
    Neurorehabil Neural Repair; 2010; 24(3):225-34. PubMed ID: 19959829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal design considerations to optimize power to detect variances and covariances among rates of change: simulation results based on actual longitudinal studies.
    Rast P; Hofer SM
    Psychol Methods; 2014 Mar; 19(1):133-54. PubMed ID: 24219544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size estimation for GEE method for comparing slopes in repeated measurements data.
    Jung SH; Ahn C
    Stat Med; 2003 Apr; 22(8):1305-15. PubMed ID: 12687656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical power, sample size, and their reporting in randomized controlled trials.
    Moher D; Dulberg CS; Wells GA
    JAMA; 1994 Jul; 272(2):122-4. PubMed ID: 8015121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical power in parallel group point exposure studies with time-to-event outcomes: an empirical comparison of the performance of randomized controlled trials and the inverse probability of treatment weighting (IPTW) approach.
    Austin PC; Schuster T; Platt RW
    BMC Med Res Methodol; 2015 Oct; 15():87. PubMed ID: 26472109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological and conceptual issues regarding occupational psychosocial coronary heart disease epidemiology.
    Burr H; Formazin M; Pohrt A
    Scand J Work Environ Health; 2016 May; 42(3):251-5. PubMed ID: 26960179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical power for analyses of changes in randomized controlled trials.
    Tu YK; Blance A; Clerehugh V; Gilthorpe MS
    J Dent Res; 2005 Mar; 84(3):283-7. PubMed ID: 15723872
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.